Brief: Herantis Pharma Evaluates Alternatives To Finance Its Research & Development Pipeline

Herantis Pharma Oyj

11/11/2020 11:04

Nov 11 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMA EVALUATES ALTERNATIVES TO FINANCE ITS
RESEARCH &
DEVELOPMENT PIPELINE AND WILL CONVENE AN EXTRAORDINARY GENERAL
MEETING
    * ASSESSMENT OF DIFFERENT FINANCING OPTIONS IS ONGOING,
INCLUDING
AMOUNT OF PURSUED FINANCING, AND TIMING THEREOF
    * ANY SHARE ISSUES AND EQUITY FINANCING TRANSACTIONS RELATED
TO
ASSESSMENT WOULD BE INTENDED TO BE CARRIED OUT FROM Q4 2020
THROUGH END OF 2021
    * BOARD WILL PROPOSE TO EGM THAT AUTHORIZATIONS ARE GRANTED
FOR
BOARD TO RESOLVE ON POTENTIAL SHARE ISSUES

Source text for Eikon:  ID:nWkr5v2fPJ 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))